Biogen Initiates Phase 3 Study of Omaveloxolone in Children with Friedreich's Ataxia
- Márcio
- Jul 21
- 1 min read
Biogen has begun a new Phase 3 study testing omaveloxolone in children ages 2 to 15 with Friedreich's ataxia. They also released a letter with more information to the community.
See Biogen's open letter to NAF and patients dated June 18, 2025 to learn more.
